Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,934 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients.
Zhou Z, Ding Z, Yuan J, Shen S, Jian H, Tan Q, Yang Y, Chen Z, Luo Q, Cheng X, Yu Y, Niu X, Qian L, Chen X, Gu L, Liu R, Ma S, Huang J, Chen T, Li Z, Ji W, Song L, Shen L, Jiang L, Yu Z, Zhang C, Tai Z, Wang C, Chen R, Carbone DP, Xia X, Lu S. Zhou Z, et al. Among authors: yuan j. J Hematol Oncol. 2022 May 18;15(1):62. doi: 10.1186/s13045-022-01283-7. J Hematol Oncol. 2022. PMID: 35585646 Free PMC article.
Dynamic alterations of ctDNA associate with the therapeutic outcome in the advanced non-small cell lung cancer patients who received sintilimab plus anlotinib regime as 1st line therapy.
Chu T, Yuan J, Lu J, Nie W, Zhong R, Zhang B, Zhang W, Shi C, Qian J, Zhang Y, Zhang X, Teng J, Gao Z, Lou Y, Li J, Qiang H, Zhang C, Li J, Xia X, Zhong H, Han B. Chu T, et al. Among authors: yuan j. Clin Transl Med. 2023 Jun;13(6):e1277. doi: 10.1002/ctm2.1277. Clin Transl Med. 2023. PMID: 37254636 Free PMC article. No abstract available.
Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer.
Han Y, Wang J, Sun T, Ouyang Q, Li J, Yuan J, Xu B. Han Y, et al. Among authors: yuan j. Signal Transduct Target Ther. 2023 Nov 17;8(1):429. doi: 10.1038/s41392-023-01672-5. Signal Transduct Target Ther. 2023. PMID: 37973901 Free PMC article.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study.
Lin D, Xiao H, Yang K, Li J, Ye S, Liu Y, Jing S, Lin Y, Yang Y, Huang L, Yuan J, Li Z, Yang J, Gao H, Xie Y, Xu M, Yan L. Lin D, et al. Among authors: yuan j. BMC Med. 2024 May 29;22(1):209. doi: 10.1186/s12916-024-03394-z. BMC Med. 2024. PMID: 38807146
Matrix metalloproteinases targeting in prostate cancer.
Zhu S, He J, Yin L, Zhou J, Lian J, Ren Y, Zhang X, Yuan J, Wang G, Li X. Zhu S, et al. Among authors: yuan j. Urol Oncol. 2024 May 27:S1078-1439(24)00459-9. doi: 10.1016/j.urolonc.2024.05.002. Online ahead of print. Urol Oncol. 2024. PMID: 38806387 Review.
14,934 results
You have reached the last available page of results. Please see the User Guide for more information.